These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12574398)

  • 41. Residues in the gp41 Ectodomain Regulate HIV-1 Envelope Glycoprotein Conformational Transitions Induced by gp120-Directed Inhibitors.
    Pacheco B; Alsahafi N; Debbeche O; Prévost J; Ding S; Chapleau JP; Herschhorn A; Madani N; Princiotto A; Melillo B; Gu C; Zeng X; Mao Y; Smith AB; Sodroski J; Finzi A
    J Virol; 2017 Mar; 91(5):. PubMed ID: 28003492
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Vaccination with the Conserved Caveolin-1 Binding Motif in Human Immunodeficiency Virus Type 1 Glycoprotein gp41 Delays the Onset of Viral Infection and Provides Partial Protection in Simian/Human Immunodeficiency Virus-Challenged Cynomolgus Macaques.
    Hovanessian AG; Soundaramourty C; Benferhat R; Le Grand R; Dereuddre-Bosquet N; Krust B; Estaquier J
    J Virol; 2018 Sep; 92(18):. PubMed ID: 29976675
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Changes in the reactivity and neutralizing activity of a type-specific neutralizing monoclonal antibody induced by interaction of soluble CD4 with gp120.
    Maeda Y; Matsushita S; Hattori T; Murakami T; Takatsuki K
    AIDS Res Hum Retroviruses; 1992 Dec; 8(12):2049-54. PubMed ID: 1493053
    [TBL] [Abstract][Full Text] [Related]  

  • 44. eCD4-Ig Variants That More Potently Neutralize HIV-1.
    Fetzer I; Gardner MR; Davis-Gardner ME; Prasad NR; Alfant B; Weber JA; Farzan M
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593050
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Monensin in lipid emulsion for the potentiation of ricin A chain immunotoxins.
    Griffin T; Raso V
    Cancer Res; 1991 Aug; 51(16):4316-22. PubMed ID: 1868454
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Anti-HIV double variable domain immunoglobulins binding both gp41 and gp120 for targeted delivery of immunoconjugates.
    Craig RB; Summa CM; Corti M; Pincus SH
    PLoS One; 2012; 7(10):e46778. PubMed ID: 23056448
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Adoptive transfer of aminobisphonate-expanded Vγ9Vδ2+ T cells does not control HIV replication in a humanized mouse model.
    Poonia B
    Immunotherapy; 2016 May; 8(5):521-6. PubMed ID: 27140407
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Chimeric viruses expressing primary envelope glycoproteins of human immunodeficiency virus type I show increased sensitivity to neutralization by human sera.
    McKeating JA; Zhang YJ; Arnold C; Frederiksson R; Fenyö EM; Balfe P
    Virology; 1996 Jun; 220(2):450-60. PubMed ID: 8661395
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Continuous presence of CD4-PE40 is required for antiviral activity against single-passage HIV isolates and infected peripheral blood mononuclear cells.
    Winters MA; Merigan TC
    AIDS Res Hum Retroviruses; 1993 Nov; 9(11):1091-6. PubMed ID: 8312052
    [TBL] [Abstract][Full Text] [Related]  

  • 50. HIV. The modern era of HIV-1 vaccine development.
    Mascola JR
    Science; 2015 Jul; 349(6244):139-40. PubMed ID: 26160931
    [No Abstract]   [Full Text] [Related]  

  • 51. Production of a human anti-CD4 monoclonal antibody with antiidiotype to anti-HIV type 1 glycoprotein 120.
    Karpatkin S; Nardi MA; Liu LX; Kouri YH; Borkowsky W
    AIDS Res Hum Retroviruses; 1995 Apr; 11(4):509-15. PubMed ID: 7632465
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Induction of human immunodeficiency virus neutralizing antibodies using fusion complexes.
    Zipeto D; Matucci A; Ripamonti C; Scarlatti G; Rossolillo P; Turci M; Sartoris S; Tridente G; Bertazzoni U
    Microbes Infect; 2006 May; 8(6):1424-33. PubMed ID: 16702010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Therapeutic potential of anti-HIV immunotoxins.
    Pincus SH
    Antiviral Res; 1996 Dec; 33(1):1-9. PubMed ID: 8955848
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Improbability of harmful autoimmune responses resulting from immunization with HIV-1 envelope glycoproteins.
    Neurath AR; Strick N; Li YY; Jiang S
    AIDS Res Hum Retroviruses; 1993 Dec; 9(12):1195-208. PubMed ID: 8142138
    [TBL] [Abstract][Full Text] [Related]  

  • 55. B cell epitope mapping of human immunodeficiency virus envelope glycoproteins with long (19- to 36-residue) synthetic peptides.
    Neurath AR; Strick N; Lee ES
    J Gen Virol; 1990 Jan; 71 ( Pt 1)():85-95. PubMed ID: 1689372
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Antiviral Activity of HIV gp120-Targeting Bispecific T Cell Engager Antibody Constructs.
    Brozy J; Schlaepfer E; Mueller CKS; Rochat MA; Rampini SK; Myburgh R; Raum T; Kufer P; Baeuerle PA; Muenz M; Speck RF
    J Virol; 2018 Jul; 92(14):. PubMed ID: 29720517
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Antigenic implications of human immunodeficiency virus type 1 envelope quaternary structure: oligomer-specific and -sensitive monoclonal antibodies.
    Broder CC; Earl PL; Long D; Abedon ST; Moss B; Doms RW
    Proc Natl Acad Sci U S A; 1994 Nov; 91(24):11699-703. PubMed ID: 7972127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Analysis of endoproteolytic cleavage and intracellular transport of human immunodeficiency virus type 1 envelope glycoproteins using mutant CD4 molecules bearing the transmembrane endoplasmic reticulum retention signal.
    Raja NU; Vincent MJ; Jabbar MA
    J Gen Virol; 1993 Oct; 74 ( Pt 10)():2085-97. PubMed ID: 8409933
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Lack of ADCC Breadth of Human Nonneutralizing Anti-HIV-1 Antibodies.
    Bruel T; Guivel-Benhassine F; Lorin V; Lortat-Jacob H; Baleux F; Bourdic K; Noël N; Lambotte O; Mouquet H; Schwartz O
    J Virol; 2017 Apr; 91(8):. PubMed ID: 28122982
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Conformational Epitope-Specific Broadly Neutralizing Plasma Antibodies Obtained from an HIV-1 Clade C-Infected Elite Neutralizer Mediate Autologous Virus Escape through Mutations in the V1 Loop.
    Patil S; Kumar R; Deshpande S; Samal S; Shrivastava T; Boliar S; Bansal M; Chaudhary NK; Srikrishnan AK; Murugavel KG; Solomon S; Simek M; Koff WC; Goyal R; Chakrabarti BK; Bhattacharya J
    J Virol; 2016 Jan; 90(7):3446-57. PubMed ID: 26763999
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.